CapWealth Advisors LLC Has $10.29 Million Stock Position in Amgen Inc. $AMGN

Key Points

• CapWealth Advisors LLC increased its position in Amgen Inc. by 5.0%, now owning 36,867 shares valued at approximately $10.29 million.
• Amgen's recent earnings report showed a net margin of 18.96% with a quarterly revenue of $9.18 billion, surpassing analysts' expectations.
• Major institutional investors own 76.50% of Amgen's stock, reflecting growing confidence from large financial entities in the company's prospects.

CapWealth Advisors LLC lifted its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 5.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 36,867 shares of the medical research company's stock after buying an additional 1,748 shares during the quarter. CapWealth Advisors LLC's holdings in Amgen were worth $10,294,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Wealth Preservation Advisors LLC acquired a new stake in shares of Amgen during the first quarter worth $25,000. First Pacific Financial increased its position in shares of Amgen by 304.5% during the first quarter. First Pacific Financial now owns 89 shares of the medical research company's stock worth $28,000 after buying an additional 67 shares during the period. CBIZ Investment Advisory Services LLC increased its position in shares of Amgen by 1,214.3% during the first quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company's stock worth $29,000 after buying an additional 85 shares during the period. Activest Wealth Management increased its position in shares of Amgen by 3,433.3% during the first quarter. Activest Wealth Management now owns 106 shares of the medical research company's stock worth $33,000 after buying an additional 103 shares during the period. Finally, Nova Wealth Management Inc. increased its position in shares of Amgen by 12,200.0% during the first quarter. Nova Wealth Management Inc. now owns 123 shares of the medical research company's stock worth $38,000 after buying an additional 122 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of the firm's stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total value of $376,286.33. Following the transaction, the senior vice president directly owned 7,209 shares of the company's stock, valued at approximately $2,141,000.91. This trade represents a 14.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.76% of the company's stock.

Wall Street Analysts Forecast Growth

AMGN has been the subject of several recent analyst reports. Morgan Stanley increased their price objective on shares of Amgen from $330.00 to $333.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. Bank of America increased their price objective on shares of Amgen from $261.00 to $272.00 and gave the stock an "underperform" rating in a research report on Friday, September 26th. William Blair reissued an "outperform" rating on shares of Amgen in a research note on Tuesday, June 24th. Weiss Ratings raised shares of Amgen from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, October 8th. Finally, Raymond James Financial initiated coverage on shares of Amgen in a research note on Wednesday, September 3rd. They set a "market perform" rating on the stock. Seven equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Amgen currently has an average rating of "Hold" and an average target price of $305.50.

Amgen Stock Up 1.0%

Amgen stock opened at $298.81 on Friday. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $335.88. The firm has a market capitalization of $160.87 billion, a price-to-earnings ratio of 24.43, a price-to-earnings-growth ratio of 2.61 and a beta of 0.49. The firm's fifty day moving average price is $287.14 and its two-hundred day moving average price is $287.27. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 7.24.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, beating analysts' consensus estimates of $5.28 by $0.74. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The firm had revenue of $9.18 billion for the quarter, compared to analyst estimates of $8.86 billion. During the same period last year, the firm earned $4.97 earnings per share. The business's quarterly revenue was up 9.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. On average, equities research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 12th. Shareholders of record on Friday, August 22nd were paid a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date of this dividend was Friday, August 22nd. Amgen's dividend payout ratio (DPR) is 77.84%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.